Crispr Therapeutics

Crispr Therapeutics

Yahoo Finance • 2 days ago

Vertex Slumps On Light Pain Drug Sales, But A Key Kidney Catalyst Lies Ahead

Vertex stock slumped Tuesday despite notching a definitive beat for its Crispr-partnered blood diseases gene editor, Casgevy. Continue Reading... Full story

Yahoo Finance • 3 days ago

Vertex Yo-Yos On Mixed Third-Quarter Report, Light Guidance Hike

Vertex stock rose late Monday on better-than-expected third-quarter sales and a guidance boost following its Crinetics close. Continue Reading... Full story

Yahoo Finance • 3 days ago

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results

CRISPR Therapeutics AG – CASGEVY® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third quarter of 2025 – – CASGEVY approved in the U.K. for children 5 years of age and older with... Full story

Yahoo Finance • 17 days ago

Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast

Cathie Wood’s Ark Invest increased its exposure to AI infrastructure, digital platforms, and biotechnology, led by purchases of $25.9M of CoreWeave (CRWV [https://seekingalpha.com/symbol/CRWV]), $24.4M of Meta Platforms (META [https://seek... Full story

Yahoo Finance • 19 days ago

Insider trades: PepsiCo (PEP), Costco (COST), BlackBerry (BB) among notable names

[Can and glass of Pepsi cola] Fotoatelie Insider trades occurred at firms including PepsiCo (PEP [https://seekingalpha.com/symbol/PEP]), Costco (COST [https://seekingalpha.com/symbol/COST]), and BlackBerry (BB [https://seekingalpha.com/sy... Full story

Yahoo Finance • last month

Billionaire Ken Fisher Was Buying These 2 Cathie Wood Stocks

Q2 13F filings show that billionaire Ken Fisher's Fisher Asset Management opened new positions in CRISPR Therapeutics (NASDAQ: CRSP) and Coinbase Global (NASDAQ: COIN). Fisher's fund bought 77,960 CRISPR Therapeutics shares valued at abou... Full story

Yahoo Finance • last month

Autologous Hematopoietic Stem Cell Gene Therapy Market Global Report 2026: A $13.44 Billion Market by 2030 as Novartis, Vertex, CRISPR Therapeutics and Orchard Therapeutics Accelerate the Gene-Editing Race

Company Logo Boost ROI via rare-disease R&D, CRISPR therapies, scalable manufacturing, CDMO partnerships and regulatory incentives that accelerate approvals and commercialization. Autologous Hematopoietic Stem Cell Gene Therapy MarketAut... Full story

Yahoo Finance • 2 months ago

3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026

It's been a disappointing couple of years for shareholders of biotechnology outfit CRISPR Therapeutics (NASDAQ: CRSP). This stock's barely up since the end of 2022, lagging the broad market's gains. It's not the performance that investors... Full story

Yahoo Finance • 2 months ago

Cathie Wood Makes Striking Switch Between AI Stock Giants

This article first appeared on GuruFocus. Cathie Wood's Ark Invest made a sharp rotation across technology and biotechnology stocks last week, buying roughly $28 million of Meta Platforms (NASDAQ:META) while selling a nearly identical dol... Full story

Yahoo Finance • 2 months ago

Cathie Wood buys $27.9 million of surging megacap stock

Cathie Wood, head of Ark Investment Management, often buys her favorite tech stocks when she sees a new opportunity. That's what she did last week, pouring $27.9 million into Meta Platforms (META) as the company pushes deeper into AI. La... Full story

Yahoo Finance • 2 months ago

AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between a mature pharmaceutical giant and a speculative gene-editing pioneer requires a clear understanding of your personal risk tolerance. Do you prefer AbbVie (NYSE:ABBV) or CRISPR Therapeutics (NASDAQ:CRSP) in 2026? AbbVie is... Full story

Yahoo Finance • 2 months ago

Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between Amgen (NASDAQ:AMGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) requires balancing the stability of a diversified pharmaceutical giant against the high-growth, high-margin profile of a specialized biotechnology pioneer. Amge... Full story

Yahoo Finance • 2 months ago

Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Investors often face a choice between the stability of established giants and the high-stakes potential of clinical-stage innovators. Deciding between Amgen (NASDAQ:AMGN) and CRISPR Therapeutics (NASDAQ:CRSP) requires balancing immediate d... Full story

Yahoo Finance • 2 months ago

Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The healthcare sector is evolving as traditional drug development meets revolutionary gene editing. Investors are now choosing between Axsome Therapeutics (NASDAQ:AXSM) and CRISPR Therapeutics (NASDAQ:CRSP) for their medical portfolios. A... Full story

Yahoo Finance • 2 months ago

Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue?

A month has gone by since the last earnings report for Rocket Pharmaceuticals (RCKT). Shares have added about 6% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings releas... Full story

Yahoo Finance • 2 months ago

Where Will CRISPR Therapeutics Stock Be in 5 Years?

CRISPR Therapeutics (NASDAQ: CRSP) has already accomplished something most gene-editing companies are still trying to do: get a CRISPR-based medicine approved and onto the market. Now it has to prove it can build a business around the tech... Full story

Yahoo Finance • 2 months ago

Cathie Wood buys $3.5 million of surging tech stock

Cathie Wood, chief of Ark Investment Management, often adds to her favorite stocks when prices swing. This time, according to an email shared with TheStreet, she's buying $3.5 million of Robinhood stock, reversing her recent sales as the... Full story

Yahoo Finance • 2 months ago

Why Is CRISPR Therapeutics (CRSP) Up 7.1% Since Last Earnings Report?

It has been about a month since the last earnings report for CRISPR Therapeutics AG (CRSP). Shares have added about 7.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earning... Full story

Yahoo Finance • 2 months ago

Investors Shrug Off Good News for Heart Patients From New Meds

Impressive results came out on drugs from Amgen, Arrowhead Pharmaceuticals, and Crispr Therapeutics. Their shares are all lower this week. Continue Reading... Full story

Yahoo Finance • 2 months ago

Cathie Wood buys $53 million of popular semiconductor stock

Cathie Wood, chief of Ark Investment Management, often uses post-earnings swings to add to her favorite tech stocks. This week, she's buying more Nvidia, adding $53 million to her stake as the stock pulled back a day after surging on bett... Full story